SLC5A2 and type 2 diabetes mellitus: A generally accepted mechanism underlying the benefits on kidney outcomes of SGLT2 inhibitors is that these agents restore tubuloglomerular feedback and thereby reduce glomerular hyperfiltration through dilation of the efferent arteriole (in type 2 diabetes) or constriction of the afferent arteriole (in hyperfiltering type 1 diabetes) [1,10,11].